Ge revolution evo ct scanner

Chest CT were obtained on a 128-slice scanner (GE Revolution EVO CT Scanner, GE Medical Systems, Milwaukee, WI, USA), with patients in supine position and during end-inspiration, without iodinated contrast medium injection. The following technical parameters were used: tube voltage: 120 kV; tube current modulation: 100–250 mAs; spiral pitch factor: 0.98; collimation width: 0.625. Images were reconstructed with a sharp convolution kernel (BONEPLUS) at a slice thickness of 1.25 mm.

All CT exams were performed with a 128-slice CT scanner (GE Revolution EVO CT Scanner, GE Medical Systems, Milwaukee, WI, USA). CT scans were acquired in the cranio-caudal direction with patients placed in a supine position in full end-inspiration with hands above the head. Patients were scanned from the xiphoid process to the pelvic floor. Considering the oncologic population enrolled, multiphase CT examinations were performed (unenhanced, arterial phase, portal phase and delayed phase), but only the unenhanced phase was used for the purpose of the analysis. Internal institution standard acquisition protocol was applied with scan parameters as follows: tube voltage 100 kV, tube current modulation 200–480 mAs, spiral pitch factor 0.98, collimation width 0.625 and gantry rotation time 0.6 s.

This prospective study was approved by local institutional review board and written informed consent was obtained from all patients. From February 2021 until September 2021 consecutive patients undergoing elective CCTA for known or suspected CAD were enrolled. Patients with contraindication to iodine contrast medium injection, renal insufficiency (eGFR < 30 mL/min/1.73 m²), previous bypass grafts or coronary stenting, and unstable angina pectoris, were not included in this study. Patients with a heart rate (HR) > 75 bpm were treated with intravenous beta-blocker (metoprolol tartrate, 5 mg). Nitrates were sublingually administrated to all patients, after exclusion of contraindications, to induce vasodilation (Trinitrine, 0.8 mg).
Patients were randomly assigned (1:1 ratio, blocks of ten) into two groups: patients in group 1 had the CCTA acquired on GE Revolution EVO CT Scanner (GE Healthcare, Milwaukee, WI, USA), while patients in group 2 had the CCTA performed on Brilliance iCT (Philips Healthcare, Cleveland, OH, USA). Each examination was eventually evaluated on the respective vendor proprietary advanced cardiac software.